Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

相关实验视频

Updated: Jul 2, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

埃特拉西莫德:第一次批准

Matt Shirley1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 22, 2024
PubMed
概括
此摘要是机器生成的。

选择性基-1-酸盐 (S1P) 受体调节剂Etrasimod获得了FDA和EMA对性结肠炎的批准. 这种口服药物针对特定的S1P亚型,为炎症性疾病提供了新的治疗方法.

更多相关视频

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

相关实验视频

Last Updated: Jul 2, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

科学领域:

  • 免疫学和药理学
  • 胃肠病学 胃肠病学

背景情况:

  • 埃特拉西莫德是一种口服的小分子选择性斯芬戈-1-酸盐 (S1P) 受体调节剂.
  • 它选择性地准S1P受体亚型S1P1,S1P4和S1P5,对S1P3的活性最小,对S1P2没有活性.

研究的目的:

  • 总结一下埃特拉西莫德的开发里程碑,从而使其获得首次批准.
  • 为了突出治疗性结肠炎的监管批准.

主要方法:

  • 对etrasimod的临床开发和监管提交的审查.
  • 对埃特拉西莫德的药理概况和选择性的分析.

主要成果:

  • 埃特拉西莫德于2023年10月获得美国FDA批准,用于成人中度至重度活性的性结肠炎.
  • 欧洲药品署建议在2023年12月向16岁及以上的患者推出营销许可,这些患者对现有疗法反应不足.

结论:

  • 埃特拉西莫德在治疗性结肠炎方面取得了重大进展.
  • 目前正在进行的临床开发针对其他免疫介导的炎症性疾病,包括克罗恩病和亚托皮炎.